We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TRN:MILTerna S.p.A. Analysis

Data as of 2026-03-13 - not real-time

€10.02

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Terna’s shares are trading at €10.02, comfortably above the 20‑day (€9.95), 50‑day (€9.54) and 200‑day (€8.94) simple moving averages, confirming a bullish price trend. The RSI sits at 59, indicating room for upside, but the MACD shows a bearish signal with the histogram turning negative, suggesting short‑term momentum may be waning. Valuation metrics are mixed: the PE ratio of 18.6 is below the industry average of 23.3, yet the DCF‑derived fair value of €7.96 implies a ~‑6.6% downside from current levels, flagging the stock as potentially overvalued. Fundamentally, the company delivers strong operating margins (44% operating, 28% net) and a robust dividend yield of 4%, but a high payout ratio of 74% and negative free cash flow raise questions about dividend sustainability. The balance sheet is heavily leveraged, with a debt‑to‑equity ratio near 189, while cash reserves are sizable but insufficient to offset the debt load. Risk‑wise, volatility is moderate at 18.9% over 30 days, beta is low, and the regulated utility sector typically carries low sector risk, though regulatory and debt‑related risks remain medium.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price trading above short‑term moving averages
  • MACD bearish crossover despite bullish trend
  • support level near €9.58 offering downside cushion

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • steady revenue growth of ~10% and strong margins
  • attractive 4% dividend yield but high 74% payout ratio
  • elevated debt‑to‑equity ratio limiting financial flexibility

Long Term

> 3 years
Cautious
Model confidence: 5/10

Key Factors

  • DCF fair value (€7.96) well below current market price (€10.02)
  • negative free cash flow indicating cash generation pressure
  • large debt burden that could constrain future upside

Key Metrics & Analysis

Financial Health

Revenue Growth10.60%
Profit Margin28.33%
P/E Ratio18.6
ROE14.28%
ROA4.39%
Debt/Equity189.07
P/B Ratio3.5
Op. Cash Flow€1.8B
Free Cash Flow€-607924992
Industry P/E23.3

Technical Analysis

TrendBullish
RSI59.7
Support€9.58
Resistance€10.25
MA 20€9.95
MA 50€9.54
MA 200€8.94
MACDBearish
VolumeIncreasing
Fear & Greed Index73.38

Valuation

Fair Value€7.96
Target Price€9.36
Upside/Downside-6.59%
GradeOvervalued
TypeValue
Dividend Yield4.00%

Risk Assessment

Beta0.11
Volatility18.85%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.